Dual Alcohol Biomarker Testing Implementation

Clinical Testing Update: 

Aria Diagnostics has successfully validated a combined alcohol biomarker panel that reports both ethanol (EtOH) and ethyl glucuronide (EtG) on the same urine specimen. All dual-marker results undergo a creatinine-based normalization protocol to flag concentrated, dilute, or non-physiologic specimens before EtOH/EtG findings are read. Aria utilizes high sensitivity, validated cutoffs of EtOH ≥25 mg/dL and EtG ≥500 ng/mL — establishing a lower, clinically actionable EtOH threshold than the 100 mg/dL cutoff historically relied upon in incumbent forensic assays.


Testing EtOH and EtG answer different clinical questions.

  • Ethanol (EtOH): As unmetabolized alcohol, EtOH serves as an acute point-in-time diagnostic. Detected for only 6-12 hours, a positive EtOH result indicates very recent drinking. The patient may be actively impaired or intoxicated at the moment of specimen collection.
  • Ethyl Glucuronide (EtG): EtG is a direct, non-oxidative metabolite that remains detectable for up to 80 hours or longer following heavy, sustained drinking. It provides an extended window into patient alcohol consumption behavior between clinic visits. Extended detection times have been directly validated in alcohol-dependent patients under controlled detoxification monitoring (Helander et al., 2009).

Run concurrently, these two markers resolve the clinical ambiguity that testing only one analyte introduces to medical providers.

  • EtG-positive / EtOH-negative: The most common pattern observed in the Aria laboratory. This result is consistent with alcohol consumption in the prior 1-3 days without current acute impairment.
  • EtOH-positive / EtG-negative: A much less common result that typically points to a specimen-integrity issue rather than recent alcohol ingestion (e.g., in vitro fermentation). It may also be observed via endogenous fermentation, as occasionally seen in poorly controlled diabetics.


How This Benefits Patients and Providers

  • Comprehensive Insight: A single collection yields both an acute-impairment diagnostic and a longitudinal between-visit compliance read. This allows pain contracts and treatment agreements to be confidently enforced from a single specimen. For pain management, medication-assisted treatment (MAT), and intensive outpatient programs, distinguishing between acute intoxication and recent use dictates the clinical response. 
  • Built-in Adulteration Safeguards: Mandatory creatinine normalization ensures that intentionally dilute or concentrated specimens are flagged before a result is acted upon, protecting both the provider and the patient.
  • Defensible Interpretations: Aria provides descriptive, evidence-based interpretive language (e.g., “consistent with alcohol use in the prior 1-3 days”) rather than binary interpretation. This provides supporting documentation that holds up under audit, appeal, or peer review.

Contact labsupport@ariadxs.com if you would like to review a specific patient result or click here to review the possible testing outcomes and their interpretation. 


Clinical References

  1. Helander A, Böttcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol. 2009;44(1):55-61.
  2. Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res. 2010;34(6):955-967.
  3. Jatlow PI, O’Malley SS. Clinical utility of objective measures of alcohol consumption. Am J Addict. 2010;19(5):412-421. (Demonstrating that quantitative EtG immunoassays are a superior, objective measure of recent alcohol use compared to standard clinical and self-reporting methods).